Featured
Landmark Clinical Trial Doubles Survival in Advanced Pancreatic Cancer with Novel RAS Inhibitor
A landmark Phase III clinical trial reveals that the novel RAS(ON) inhibitor daraxonrasib doubles median overall survival in patients with previously ...
Read Full Story →